Skip to main content
Top
Published in: Diabetologia 4/2018

01-04-2018 | Article

Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function

Authors: Xiaoyu He, Qiaohong Lai, Cai Chen, Na Li, Fei Sun, Wenting Huang, Shu Zhang, Qilin Yu, Ping Yang, Fei Xiong, Zhishui Chen, Quan Gong, Boxu Ren, Jianping Weng, Décio L. Eizirik, Zhiguang Zhou, Cong-Yi Wang

Published in: Diabetologia | Issue 4/2018

Login to get access

Abstract

Aims/hypothesis

Post-translational attachment of a small ubiquitin-like modifier (SUMO) to the lysine (K) residue(s) of target proteins (SUMOylation) is an evolutionary conserved regulatory mechanism. This modification has previously been demonstrated to be implicated in the control of a remarkably versatile regulatory mechanism of cellular processes. However, the exact regulatory role and biological actions of the E2 SUMO-conjugating enzyme (UBC9)-mediated SUMOylation function in pancreatic beta cells has remained elusive.

Methods

Inducible beta cell-specific Ubc9 (also known as Ube2i) knockout (KO; Ubc9Δbeta) and transgenic (Ubc9Tg) mice were employed to address the impact of SUMOylation on beta cell viability and functionality. Ubc9 deficiency or overexpression was induced at 8 weeks of age using tamoxifen. To study the mechanism involved, we closely examined the regulation of the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) through SUMOylation in beta cells.

Results

Upon induction of Ubc9 deficiency, Ubc9Δbeta islets exhibited a 3.5-fold higher accumulation of reactive oxygen species (ROS) than Ubc9f/f control islets. Islets from Ubc9Δbeta mice also had decreased insulin content and loss of beta cell mass after tamoxifen treatment. Specifically, at day 45 after Ubc9 deletion only 40% of beta cell mass remained in Ubc9Δbeta mice, while 90% of beta cell mass was lost by day 75. Diabetes onset was noted in some Ubc9Δbeta mice 8 weeks after induction of Ubc9 deficiency and all mice developed diabetes by 10 weeks following tamoxifen treatment. In contrast, Ubc9Tg beta cells displayed an increased antioxidant ability but impaired insulin secretion. Unlike Ubc9Δbeta mice, which spontaneously developed diabetes, Ubc9Tg mice preserved normal non-fasting blood glucose levels without developing diabetes. It was noted that SUMOylation of NRF2 promoted its nuclear expression along with enhanced transcriptional activity, thereby preventing ROS accumulation in beta cells.

Conclusions/interpretation

SUMOylation function is required to protect against oxidative stress in beta cells; this mechanism is, at least in part, carried out by the regulation of NRF2 activity to enhance ROS detoxification. Homeostatic SUMOylation is also likely to be essential for maintaining beta cell functionality.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yang P, Hu S, Yang F et al (2014) Sumoylation modulates oxidative stress relevant to the viability and functionality of pancreatic beta cells. Am J Transl Res 6:353–360PubMedPubMedCentral Yang P, Hu S, Yang F et al (2014) Sumoylation modulates oxidative stress relevant to the viability and functionality of pancreatic beta cells. Am J Transl Res 6:353–360PubMedPubMedCentral
2.
go back to reference Flotho A, Melchior F (2013) Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem 82:357–385CrossRefPubMed Flotho A, Melchior F (2013) Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem 82:357–385CrossRefPubMed
3.
go back to reference Li M, Guo D, Isales CM et al (2005) SUMO wrestling with type 1 diabetes. J Mol Med (Berlin, Germany) 83:504–513CrossRef Li M, Guo D, Isales CM et al (2005) SUMO wrestling with type 1 diabetes. J Mol Med (Berlin, Germany) 83:504–513CrossRef
4.
go back to reference Hajmrle C, Ferdaoussi M, Plummer G et al (2014) SUMOylation protects against IL-1beta-induced apoptosis in INS-1 832/13 cells and human islets. Am J Phys Endocrinol Metab 307:E664–E673CrossRef Hajmrle C, Ferdaoussi M, Plummer G et al (2014) SUMOylation protects against IL-1beta-induced apoptosis in INS-1 832/13 cells and human islets. Am J Phys Endocrinol Metab 307:E664–E673CrossRef
5.
go back to reference Pandey D, Chen F, Patel A et al (2011) SUMO1 negatively regulates reactive oxygen species production from NADPH oxidases. Arterioscler Thromb Vasc Biol 31:1634–1642CrossRefPubMedPubMedCentral Pandey D, Chen F, Patel A et al (2011) SUMO1 negatively regulates reactive oxygen species production from NADPH oxidases. Arterioscler Thromb Vasc Biol 31:1634–1642CrossRefPubMedPubMedCentral
6.
go back to reference Guo D, Han J, Adam BL et al (2005) Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress. Biochem Biophys Res Commun 337:1308–1318CrossRefPubMed Guo D, Han J, Adam BL et al (2005) Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress. Biochem Biophys Res Commun 337:1308–1318CrossRefPubMed
7.
go back to reference Kishi A, Nakamura T, Nishio Y, Maegawa H, Kashiwagi A (2003) Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am J Phys Endocrinol Metab 284:E830–E840CrossRef Kishi A, Nakamura T, Nishio Y, Maegawa H, Kashiwagi A (2003) Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am J Phys Endocrinol Metab 284:E830–E840CrossRef
8.
go back to reference Mziaut H, Trajkovski M, Kersting S et al (2006) Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol 8:435–445CrossRefPubMed Mziaut H, Trajkovski M, Kersting S et al (2006) Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol 8:435–445CrossRefPubMed
10.
go back to reference Dai XQ, Kolic J, Marchi P, Sipione S, Macdonald PE (2009) SUMOylation regulates Kv2.1 and modulates pancreatic beta-cell excitability. J Cell Sci 122:775–779CrossRefPubMed Dai XQ, Kolic J, Marchi P, Sipione S, Macdonald PE (2009) SUMOylation regulates Kv2.1 and modulates pancreatic beta-cell excitability. J Cell Sci 122:775–779CrossRefPubMed
11.
go back to reference Dai XQ, Plummer G, Casimir M et al (2011) SUMOylation regulates insulin exocytosis downstream of secretory granule docking in rodents and humans. Diabetes 60:838–847CrossRefPubMedPubMedCentral Dai XQ, Plummer G, Casimir M et al (2011) SUMOylation regulates insulin exocytosis downstream of secretory granule docking in rodents and humans. Diabetes 60:838–847CrossRefPubMedPubMedCentral
12.
go back to reference Aukrust I, Bjorkhaug L, Negahdar M et al (2013) SUMOylation of pancreatic glucokinase regulates its cellular stability and activity. J Biol Chem 288:5951–5962CrossRefPubMedPubMedCentral Aukrust I, Bjorkhaug L, Negahdar M et al (2013) SUMOylation of pancreatic glucokinase regulates its cellular stability and activity. J Biol Chem 288:5951–5962CrossRefPubMedPubMedCentral
13.
go back to reference Ferdaoussi M, Dai X, Jensen MV et al (2015) Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional beta cells. J Clin Investig 125:3847–3860CrossRefPubMedPubMedCentral Ferdaoussi M, Dai X, Jensen MV et al (2015) Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional beta cells. J Clin Investig 125:3847–3860CrossRefPubMedPubMedCentral
14.
go back to reference Rajan S, Torres J, Thompson MS, Philipson LH (2012) SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion. Am J Phys Endocrinol Metab 302:E714–E723CrossRef Rajan S, Torres J, Thompson MS, Philipson LH (2012) SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion. Am J Phys Endocrinol Metab 302:E714–E723CrossRef
15.
go back to reference Rajan S, Dickson LM, Mathew E et al (2015) Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic beta-cells via protein kinase A. Mol Metab 4:265–276CrossRefPubMedPubMedCentral Rajan S, Dickson LM, Mathew E et al (2015) Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic beta-cells via protein kinase A. Mol Metab 4:265–276CrossRefPubMedPubMedCentral
16.
go back to reference Ferdaoussi M, Fu J, Dai X et al (2017) SUMOylation and calcium control syntaxin-1A and secretagogin sequestration by tomosyn to regulate insulin exocytosis in human β cells. Sci Rep 7:248CrossRefPubMedPubMedCentral Ferdaoussi M, Fu J, Dai X et al (2017) SUMOylation and calcium control syntaxin-1A and secretagogin sequestration by tomosyn to regulate insulin exocytosis in human β cells. Sci Rep 7:248CrossRefPubMedPubMedCentral
17.
go back to reference Chen L, Fan C, Zhang Y et al (2013) Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model. Prostaglandins & Other Lipid Mediators 104–105:42–48CrossRef Chen L, Fan C, Zhang Y et al (2013) Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model. Prostaglandins & Other Lipid Mediators 104–105:42–48CrossRef
18.
go back to reference Cheng J, Song J, He X et al (2016) Loss of Mbd2 protects mice against high fat diet-induced obesity and insulin resistance by regulating the homeostasis of energy storage and expenditure. Diabetes 65:3384–3395CrossRefPubMed Cheng J, Song J, He X et al (2016) Loss of Mbd2 protects mice against high fat diet-induced obesity and insulin resistance by regulating the homeostasis of energy storage and expenditure. Diabetes 65:3384–3395CrossRefPubMed
19.
go back to reference Yang P, Li M, Guo D et al (2008) Comparative analysis of the islet proteome between NOD/Lt and ALR/Lt mice. Ann N Y Acad Sci 1150:68–71CrossRefPubMed Yang P, Li M, Guo D et al (2008) Comparative analysis of the islet proteome between NOD/Lt and ALR/Lt mice. Ann N Y Acad Sci 1150:68–71CrossRefPubMed
20.
go back to reference He L, Sun F, Wang Y et al (2016) HMGB1 exacerbates bronchiolitis obliterans syndrome via RAGE/NF-kappaB/HPSE signaling to enhance latent TGF-beta release from ECM. Am J Transl Res 8:1971–1984PubMedPubMedCentral He L, Sun F, Wang Y et al (2016) HMGB1 exacerbates bronchiolitis obliterans syndrome via RAGE/NF-kappaB/HPSE signaling to enhance latent TGF-beta release from ECM. Am J Transl Res 8:1971–1984PubMedPubMedCentral
21.
go back to reference Han J, Zhong J, Wei W et al (2008) Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 57:2118–2127CrossRefPubMedPubMedCentral Han J, Zhong J, Wei W et al (2008) Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 57:2118–2127CrossRefPubMedPubMedCentral
22.
go back to reference Ran L, Yu Q, Zhang S et al (2015) Cx3cr1 deficiency in mice attenuates hepatic granuloma formation during acute schistosomiasis by enhancing the M2-type polarization of macrophages. Dis Model Mech 8:691–700CrossRefPubMedPubMedCentral Ran L, Yu Q, Zhang S et al (2015) Cx3cr1 deficiency in mice attenuates hepatic granuloma formation during acute schistosomiasis by enhancing the M2-type polarization of macrophages. Dis Model Mech 8:691–700CrossRefPubMedPubMedCentral
23.
go back to reference Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z (2004) Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 279:19948–19954CrossRefPubMed Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z (2004) Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 279:19948–19954CrossRefPubMed
24.
go back to reference Zhang M, Guo Y, Fu H et al (2015) Chop deficiency prevents UUO-induced renal fibrosis by attenuating fibrotic signals originated from Hmgb1/TLR4/NFkappaB/IL-1beta signaling. Cell Death Dis 6:e1847CrossRefPubMedPubMedCentral Zhang M, Guo Y, Fu H et al (2015) Chop deficiency prevents UUO-induced renal fibrosis by attenuating fibrotic signals originated from Hmgb1/TLR4/NFkappaB/IL-1beta signaling. Cell Death Dis 6:e1847CrossRefPubMedPubMedCentral
25.
go back to reference Yao Y, Wang Y, Zhang Z et al (2016) Chop deficiency protects mice against bleomycin-induced pulmonary fibrosis by attenuating M2 macrophage production. Mol Ther J Am Soc Gene Ther 24:915–925CrossRef Yao Y, Wang Y, Zhang Z et al (2016) Chop deficiency protects mice against bleomycin-induced pulmonary fibrosis by attenuating M2 macrophage production. Mol Ther J Am Soc Gene Ther 24:915–925CrossRef
27.
go back to reference Liang H, Yin B, Zhang H et al (2008) Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF-alpha signaling protected Wistar rats from diet-induced obesity and insulin resistance. Endocrinology 149:2943–2951CrossRefPubMed Liang H, Yin B, Zhang H et al (2008) Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF-alpha signaling protected Wistar rats from diet-induced obesity and insulin resistance. Endocrinology 149:2943–2951CrossRefPubMed
28.
go back to reference Jakobs A, Koehnke J, Himstedt F et al (2007) Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation. Nat Methods 4:245–250CrossRefPubMed Jakobs A, Koehnke J, Himstedt F et al (2007) Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation. Nat Methods 4:245–250CrossRefPubMed
29.
go back to reference Wei W, Yang P, Pang J et al (2008) A stress-dependent SUMO4 sumoylation of its substrate proteins. Biochem Biophys Res Commun 375:454–459CrossRefPubMed Wei W, Yang P, Pang J et al (2008) A stress-dependent SUMO4 sumoylation of its substrate proteins. Biochem Biophys Res Commun 375:454–459CrossRefPubMed
30.
go back to reference Wang CY, Yang P, Li M, Gong F (2009) Characterization of a negative feedback network between SUMO4 expression and NFkappaB transcriptional activity. Biochem Biophys Res Commun 381:477–481CrossRefPubMed Wang CY, Yang P, Li M, Gong F (2009) Characterization of a negative feedback network between SUMO4 expression and NFkappaB transcriptional activity. Biochem Biophys Res Commun 381:477–481CrossRefPubMed
31.
go back to reference Pi J, Collins S (2010) Reactive oxygen species and uncoupling protein 2 in pancreatic beta-cell function. Diabetes Obes Metab 12(Suppl 2):141–148CrossRefPubMed Pi J, Collins S (2010) Reactive oxygen species and uncoupling protein 2 in pancreatic beta-cell function. Diabetes Obes Metab 12(Suppl 2):141–148CrossRefPubMed
33.
go back to reference Bhakkiyalakshmi E, Shalini D, Sekar TV, Rajaguru P, Paulmurugan R, Ramkumar KM (2014) Therapeutic potential of pterostilbene against pancreatic beta-cell apoptosis mediated through Nrf2. Br J Pharmacol 171:1747–1757CrossRefPubMedPubMedCentral Bhakkiyalakshmi E, Shalini D, Sekar TV, Rajaguru P, Paulmurugan R, Ramkumar KM (2014) Therapeutic potential of pterostilbene against pancreatic beta-cell apoptosis mediated through Nrf2. Br J Pharmacol 171:1747–1757CrossRefPubMedPubMedCentral
34.
go back to reference Yagishita Y, Fukutomi T, Sugawara A et al (2014) Nrf2 protects pancreatic beta-cells from oxidative and nitrosative stress in diabetic model mice. Diabetes 63:605–618CrossRefPubMed Yagishita Y, Fukutomi T, Sugawara A et al (2014) Nrf2 protects pancreatic beta-cells from oxidative and nitrosative stress in diabetic model mice. Diabetes 63:605–618CrossRefPubMed
35.
go back to reference Cunha DA, Cito M, Carlsson PO et al (2016) Thrombospondin 1 protects pancreatic beta-cells from lipotoxicity via the PERK-NRF2 pathway. Cell Death Differ 23:1995–2006CrossRefPubMedPubMedCentral Cunha DA, Cito M, Carlsson PO et al (2016) Thrombospondin 1 protects pancreatic beta-cells from lipotoxicity via the PERK-NRF2 pathway. Cell Death Differ 23:1995–2006CrossRefPubMedPubMedCentral
36.
go back to reference Ramani K, Tomasi ML, Yang H, Ko K, Lu SC (2012) Mechanism and significance of changes in glutamate-cysteine ligase expression during hepatic fibrogenesis. J Biol Chem 287:36341–36355CrossRefPubMedPubMedCentral Ramani K, Tomasi ML, Yang H, Ko K, Lu SC (2012) Mechanism and significance of changes in glutamate-cysteine ligase expression during hepatic fibrogenesis. J Biol Chem 287:36341–36355CrossRefPubMedPubMedCentral
38.
go back to reference Hourihan JM, Moronetti Mazzeo LE, Fernandez-Cardenas LP, Blackwell TK (2016) Cysteine sulfenylation directs IRE-1 to activate the SKN-1/Nrf2 antioxidant response. Mol Cell 63:553–566CrossRefPubMedPubMedCentral Hourihan JM, Moronetti Mazzeo LE, Fernandez-Cardenas LP, Blackwell TK (2016) Cysteine sulfenylation directs IRE-1 to activate the SKN-1/Nrf2 antioxidant response. Mol Cell 63:553–566CrossRefPubMedPubMedCentral
39.
go back to reference Ngo HKC, Kim DH, Cha YN, Na HK, Surh YJ (2017) Nrf2 mutagenic activation drives hepatocarcinogenesis. Cancer Res 77:4797–4808CrossRefPubMed Ngo HKC, Kim DH, Cha YN, Na HK, Surh YJ (2017) Nrf2 mutagenic activation drives hepatocarcinogenesis. Cancer Res 77:4797–4808CrossRefPubMed
40.
go back to reference Soares MA, Cohen OD, Low YC et al (2016) Restoration of Nrf2 signaling normalizes the regenerative niche. Diabetes 65:633–646CrossRefPubMed Soares MA, Cohen OD, Low YC et al (2016) Restoration of Nrf2 signaling normalizes the regenerative niche. Diabetes 65:633–646CrossRefPubMed
41.
go back to reference Saito T, Ichimura Y, Taguchi K et al (2016) p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. 7:12030 Saito T, Ichimura Y, Taguchi K et al (2016) p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. 7:12030
42.
go back to reference Rabbani PS, Zhou A, Borab ZM et al (2017) Novel lipoproteoplex delivers Keap1 siRNA based gene therapy to accelerate diabetic wound healing. Biomaterials 132:1–15CrossRefPubMed Rabbani PS, Zhou A, Borab ZM et al (2017) Novel lipoproteoplex delivers Keap1 siRNA based gene therapy to accelerate diabetic wound healing. Biomaterials 132:1–15CrossRefPubMed
43.
go back to reference Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:199–218CrossRefPubMed Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:199–218CrossRefPubMed
44.
go back to reference Itoh K, Wakabayashi N, Katoh Y et al (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13:76CrossRefPubMedPubMedCentral Itoh K, Wakabayashi N, Katoh Y et al (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13:76CrossRefPubMedPubMedCentral
Metadata
Title
Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function
Authors
Xiaoyu He
Qiaohong Lai
Cai Chen
Na Li
Fei Sun
Wenting Huang
Shu Zhang
Qilin Yu
Ping Yang
Fei Xiong
Zhishui Chen
Quan Gong
Boxu Ren
Jianping Weng
Décio L. Eizirik
Zhiguang Zhou
Cong-Yi Wang
Publication date
01-04-2018
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2018
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4523-9

Other articles of this Issue 4/2018

Diabetologia 4/2018 Go to the issue

List of Referees

Referees 2017

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.